Loading, Please Wait...
AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today reported financial results for the third quarter of 2019. As of September 30, 2019, MTEM’s cash and investments totaled $51.4 million, and is expected to fund operations through 2020.
“So far in 2019, we have reported Phase I/Ib data for MT-3724, started three Phase II studies for MT-3724, initiated a Phase I study for MT-5111, and our partner Takeda is initiating a Phase I study for TAK-169,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “We expect to provide study updates on the three ongoing MT-3724 Phase II studies and the MT-5111 Phase I study by the end of the year and continue to advance our pipeline of both clinical and preclinical stage programs into 2020.”
Company Highlights and Upcoming Milestones
TAK-169 (CD38-targted ETB)
MT-3724 (CD20-targeted ETB)
MT-5111 (HER2-targeted ETB)
Takeda Multi-Target Collaboration
The net loss attributable to common shareholders for the third quarter of 2019 was $38.2 million, or $1.03 per basic and diluted share. This compares with a net loss attributable to common shareholders of $5.2 million, or $0.19 per basic and diluted share, for the same period in 2018.
Revenues for the third quarter of 2019 were $3.6 million, compared to $6.8 million for the same period in 2018. Revenues for the third quarter of 2019 were comprised of revenues from collaborative research and development agreements with Takeda, and grant revenue from CPRIT. Total research and development expenses for the third quarter of 2019 were $15.2 million, compared with $8.3 million for the same period in 2018. Total general and administrative expenses for the third quarter of 2019 were $4.5 million, compared with $3.5 million for the same period in 2018. In the third quarter, there was also a non-cash impairment charge of $22.1 million relating to the Company’s legacy program, Evofosfamide. Specifically, loss on impairment of in-process research and development for the third quarter of 2019 was $22.1 million, compared to no loss on impairment of in-process research and development for the same period in 2018. The impairment charge related entirely to this legacy program, which the Company acquired from Threshold Pharmaceuticals in 2017, and is unrelated to the Company’s current ETB technology and related pipeline programs.
About Molecular Templates
Molecular Templates is a clinical stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells. Additional information about Molecular Templates can be obtained at http://www.mtem.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the development of the Company’s lead program, MT-3724, and the replication of monotherapy activity in the Phase II studies with MT-3724; the expected timing of submitting various IND applications, conducting studies, dosing patients, and reporting additional updates on studies or data from various studies; and the Company’s belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; the ability of the Company to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in the Company’s filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.
Chief Financial Officer
Molecular Templates, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
Three Months Ended
Nine Months Ended
|Research and development revenue - from related party||$||2,903||$||1,914||$||14,527||$||3,009|
|Research and development revenue - other||284||117||284||197|
|Research and development||15,249||8,290||33,946||22,640|
|General and administrative||4,509||3,538||14,049||10,165|
|Loss on impairment of in-process research and development||22,123||—||22,123||—|
|Total operating expenses||41,881||11,828||70,118||32,805|
|Loss from operations||38,263||5,076||54,045||24,204|
|Interest and other income, net||396||107||1,449||307|
|Interest and other expense, net||(353||)||(279||)||(947||)||(672||)|
|Change in fair value of warrant liabilities||1||4||3||916|
|Net loss attributable to common shareholders||$||38,219||$||5,244||$||53,540||$||23,653|
|Net loss per share attributable to common shareholders:|
|Basic and diluted||$||1.03||$||0.19||$||1.45||$||0.87|
|Weighted average number of shares used in net loss per share calculations:|
|Basic and diluted||36,937,912||27,680,307||36,832,966||27,246,667|
Molecular Templates, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
|Cash and cash equivalents||$||15,268||$||87,721|
|Marketable securities, current||36,147||10,234|
|Grants revenue receivable||5,591||4,329|
|Accounts receivable from related party||—||240|
|In-process research and development - held for sale||4,500||26,623|
|Other current assets||300||95|
|Total current assets||64,146||131,486|
|Operating lease right-of-use assets, non-current||10,397||—|
|Property and equipment, net||13,884||6,851|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Deferred revenue, current||11,956||26,231|
|Other current liabilities||1,623||141|
|Total current liabilities||24,098||32,509|
|Deferred revenue, non-current||1,236||2,670|
|Long-term debt, non-current, net||3,001||3,254|
|Operating lease liabilities, non-current||10,573||—|
|Commitments and contingencies (Note 9)|
|Common stock, $0.001 par value:|
|Authorized: 150,000,000 shares; issued and outstanding: 36,954,510 shares at September 30, 2019 and 36,736,012 shares at December 31, 2018||37||37|
|Additional paid-in capital||201,203||195,573|
|Accumulated other comprehensive income||20||—|
|Total stockholders’ equity||53,016||100,906|
|Total liabilities and stockholders’ equity||$||93,162||$||140,158|